Henrik Lundvall
Henrik has extensive experience in senior roles within international media and tech companies, including TT, Expressen, Microsoft, Axel Springer and Lifesum. At Yazen, he is Head of Content, with responsibility for strategy, marketing and in-app content, working closely with product, medical and tech teams.
Beyond GLP-1 medicines: the path to successful and long-term weight loss
We are in a new era of obesity treatment. GLP-1-based medicines have transformed the landscape – but real success is achieved when medication becomes part of a comprehensive approach that supports the whole person.
Long-term health and weight loss require more than medicine alone. It is when medical treatment is combined with lifestyle change and continuous guidance that meaningful, lasting progress becomes possible (1–2).
Trulicity (dulaglutide) in the treatment of obesity
Trulicity is a medicine that contains the active substance dulaglutide. It is approved for the treatment of adults with type 2 diabetes to improve glycaemic control as a complement to a healthy diet and physical activity (1). The treatment may also contribute to weight loss (2–4).
Saxenda (liraglutide) in the treatment of obesity
Saxenda is a medicine used as support in the treatment of overweight and obesity. It contains the active substance liraglutide, which influences appetite regulation and helps reduce energy intake. When combined with lifestyle changes such as a healthy diet and regular physical activity, the treatment can support clinically significant weight loss (1).
How to reduce the risk of loose skin after weight loss
Weight loss can bring significant positive changes for both health and wellbeing. At the same time, many people experience loose skin after substantial weight loss, especially if the weight has decreased rapidly or if they have lived with overweight or obesity for a long time.
Loose skin is a natural result of changes in the skin’s elasticity as the body adjusts. By understanding how the skin is affected after weight loss and which factors influence its elasticity, you can give the skin better conditions to tighten and feel firmer again.
Rybelsus (semaglutide) in the treatment of obesity
Rybelsus is a medicine containing the active substance semaglutide. It is approved for the treatment of adults with type 2 diabetes to improve glycaemic control as a complement to a healthy diet and physical activity.
The treatment may also contribute to weight loss (1,2).
Mounjaro (tirzepatide) in the treatment of obesity
Mounjaro is a medicine that can help people living with type 2 diabetes – as well as those with overweight or obesity – to regulate blood sugar, improve their health and achieve sustainable weight loss. To make an informed decision about treatment, it is important to understand how Mounjaro works, who it is suitable for, and how it can support long-term lifestyle change.
Ozempic (semaglutide) in the treatment of obesity
Ozempic is a prescription medicine containing semaglutide as its active substance. This medicine was originally approved for the treatment of type 2 diabetes, but has since also been shown to contribute to clinically significant weight loss. Semaglutide has demonstrated significant improvements in body weight and metabolic markers in studies involving individuals with overweight or obesity. To make an informed decision about treatment, it is important that the person receives accurate information about how Ozempic works, who it is suitable for, and how it may affect long-term health (1,2).
